Lupin gets tentative USFDA nod for Brivaracetam tablets

It is indicated for the treatment of partial-onset seizures in patients four years of age and older.

80
USFDA
Picture: Pixabay

Last Updated on August 20, 2021 by The Health Master

Lupin has received tentative approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Brivaracetam Tablets, 10 mg, 25 mg, 50 mg, 75 mg and 100 mg, to market a generic equivalent of Briviact tablets, 10 mg, 25 mg, 50 mg, 75 mg and 100 mg, of UCB Inc.

The product will be manufactured at Lupin’s Nagpur facility in India, Lupin said in a statement.

It notified that Brivaracetam tablets are indicated for the treatment of partial-onset seizures in patients four years of age and older.

“Brivaracetam tablets had estimated annual sales of $311 million in the US (IQVIA MAT June 2021),” it added.

Zydus Cadila gets USFDA nod for Mesalamine ER capsules

Cipla gets USFDA nod for generic Difluprednate Ophthalmic Emulsion

Alembic gets USFDA nod for Clomipramine HCL Capsules

Zydus Cadila gets final nod from USFDA for Fulvestrant injection

USFDA inspection ends with ‘Zero’ observations: Alkem

Granules Pharma clears USFDA audit

Latest Notifications regarding Pharmaceuticals

India and Pharmacy Education: Chapter: 5

Drug unit busted, NDPS drugs seized, 5 arrested

New drug discovered which corrects diet-induced obesity: Research

Govt removes DPCO 2013’s this clause on ceiling price revision

42 FDA Officers honoured on 15th August 2021: Independence Day

Telegram
WhatsApp
Facebook
LinkedIn
Google-news

Enter your email address:

Delivered by FeedBurner